Shelton Capital Management grew its stake in shares of AbbVie Inc (NYSE:ABBV) by 59.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 127,799 shares of the company’s stock after purchasing an additional 47,700 shares during the quarter. AbbVie comprises about 0.8% of Shelton Capital Management’s portfolio, making the stock its 20th biggest holding. Shelton Capital Management’s holdings in AbbVie were worth $11,356,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Hudock Capital Group LLC increased its position in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after purchasing an additional 806 shares during the last quarter. Ffcm LLC increased its position in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after purchasing an additional 963 shares during the last quarter. Bristlecone Advisors LLC acquired a new position in shares of AbbVie during the 3rd quarter worth approximately $113,000. BDO Wealth Advisors LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $115,000. Finally, Hershey Trust Co. acquired a new position in shares of AbbVie during the 3rd quarter worth approximately $139,000. 69.49% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have weighed in on ABBV shares. Societe Generale boosted their price target on AbbVie in a research report on Tuesday, November 21st. SunTrust Banks boosted their price target on AbbVie to $157.00 and gave the stock an “average” rating in a research report on Monday, January 29th. ValuEngine lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 1st. Leerink Swann set a $106.00 target price on AbbVie and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $118.44.
In related news, insider Laura J. Schumacher sold 145,510 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $96.71, for a total value of $14,072,272.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the completion of the sale, the senior vice president now owns 113,118 shares of the company’s stock, valued at $11,136,467.10. The disclosure for this sale can be found here. Insiders sold a total of 233,542 shares of company stock valued at $22,760,708 over the last 90 days. 0.23% of the stock is currently owned by corporate insiders.
AbbVie Inc (ABBV) opened at $118.75 on Friday. The company has a market capitalization of $188,571.80, a P/E ratio of 21.24, a PEG ratio of 1.13 and a beta of 1.61. AbbVie Inc has a one year low of $61.49 and a one year high of $125.86. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.32 and a current ratio of 1.28.
AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.20 EPS. research analysts anticipate that AbbVie Inc will post 7.48 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be paid a $0.96 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This is an increase from AbbVie’s previous quarterly dividend of $0.71. This represents a $3.84 annualized dividend and a yield of 3.23%. AbbVie’s payout ratio is 86.32%.
AbbVie announced that its board has initiated a stock buyback plan on Thursday, February 15th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: “AbbVie Inc (ABBV) Holdings Lifted by Shelton Capital Management” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/25/abbvie-inc-abbv-holdings-lifted-by-shelton-capital-management.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.